Skip to main content

Advertisement

Table 3 SSE risk ratio between groups

From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Variable Denosumab (n = 120) ZA(n = 122) P - value
Total SSE HR(95%CI) 12.43 19.92 0.002*
  (2.17-17.44) (3.34–21.35)  
SSE HR(95%CI)
within 2 years 6.33 7.27 0.106*
  (1.36-12.38) (1.54–19.63)  
after 2 years 36.26 83.52 0.001*
  (3.31-161.15) (4.29–92.60)  
  1. * Statistically significant values. SSEs: symptomatic skeletal events; ZA: zoledronic acid; HR: hazard ratio; CI: confidence interval